FindTrial
Sign In

A study to compare olmesartan and azilsartan in reducing high blood pressure patients

A Comparative study of efficacy, safety and tolerance of Olmesartan medoxomil and Azilsartan medoxomil in newly diagnosed patients with stage 1 Hypertension -A prospective observational open label study. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099604
Enrollment
100
Registered
2025-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Olmesartan Medoxomil: 20 mg OD,oral for 3 months Control Intervention1: Azilsartan medoxomil: 40 mg OD,oral for 3 months

Sponsors

Self
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of both sexes aged more than 18 years with stage 1 hypertension (140-159 systolic BP/90-99 diastolic BP). 2. Patients with associated co-morbid conditions as diabetes, hypothyroidism without complications. 3. Patients who are willing to give consent for the study.

Exclusion criteria

Exclusion criteria: 1. Patients with stage ll and lll hypertension. 2. Patients already on anti-hypertensive medications. 3. Patients with hypertensive urgencies and emergencies. 4. Along with additional comorbid diseases like coronary artery disease CCF, CKD, stroke and heart, kidney, liver complications. 5. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Reduction in systolic and diastolic BPTimepoint: 3 MONTHS—

Secondary

MeasureTime frame
To record adverse effects of Olmesartan and Azilsartan such as dizziness, fatigue, headache, hyperglycemia. Timepoint: 3 months—

Countries

India

Contacts

Public ContactDr Kaviya M

Vinayaka Missions Research foundation

manipoo73@gmail.com8973377443

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026